抑癌基因pten—骨髓瘤治疗新靶点  

Antioncogene pten-a New Target for Myeloma Therapy——Review

作　　者：王素云[1,2] 成志勇[3] 邓凯[4] 陈浩[1] 潘崚[1] 

机构地区：[1]河北医科大学第二医院血液内科血液实验室,河北石家庄050000 [2]河北省人民医院血液内科,河北石家庄050051 [3]河北省保定市第一医院血液内科,河北保定071000 [4]河北医科大学第二医院骨科,河北石家050000

出　　处：《中国实验血液学杂志》2010年第3期816-820,共5页Journal of Experimental Hematology

基　　金：河北省科技攻关计划项目(072761130)

摘　　要：基因pten是迄今为止发现的第一个具有双特异性磷酸酶活性的抑癌基因,通过负调控多种信号传导途径来调节细胞周期进展、细胞凋亡、肿瘤细胞迁移和侵袭。多发性骨髓瘤(MM)是发生于B细胞分化终末阶段即浆细胞阶段的恶性肿瘤,遗传学改变被认为是MM发病的重要致病因素,抑癌基因的缺失是重要的遗传学变化。然而,目前对于pten在MM中的遗传学改变知之甚少,本文综述了pten在MM领域中的研究进展,包括pten的结构及其作用机制,以及pten与骨髓瘤问题,为治疗MM寻找新的基因靶点提供参考。Pten gene is the first antioncogene with dual phosphatase activity disscovered so far, pten gene regulates the cell cycle progress, apoptosis, metastasis and invasion of the tumor cells through negatively regulating the multiple signaling transduction pathways. Multple myeloma （MM） is a malignant tumor occuring in terminal stage of B cell differentiation. The genetic changes are considered as the important factors in MM pathogenesis, among which the deletion of antioncogene is a critical genetic change. However, little is known about the genetic change of pten in MM. This review summairzes the research advance on pten in MM including structure of pten, mechanism of pten effect and correlation of pten with MM in order to provide some references for the investigating new gene target to treat the MM.

关 键 词：PTEN基因 多发性骨髓瘤 信号传导 

分 类 号：R733.3[医药卫生—肿瘤]